SELPLG and Miyoshi myopathy: In conclusion, our results demonstrate that inhibition of P-selectin/PSGL-1 axis using humanized monoclonal antibodies, SelG1 and SelK2, is promising as a treatment for MM and that these antibodies were potent (only 5 ug/mL was needed) with a very good pharmacokinetics (antibodies were injected twice a week only).